Dr. Mariam Gachechiladze's research contributes to the strategic initiatives in digital pathology and oncology, including the Swiss Digital Pathology Initiative (SDPI), BMI2/Loop and Swiss Personalized Oncology National data Stream (SPO-NDS) at the Institute of Pathology and Molecular Pathology, University of Zurich. Her work is primarily focused on the identification and validation of predictive biomarker combinations for the development of personalized therapy approaches in cancer patients, specifically for the combination therapies involving standard DNA-damaging agents, DNA damage response targeted small molecule inhibitors, and immunotherapy.

Tspan6 stimulates the chemoattractive potential of breast cancer cells for B cells in an EV- and LXR-dependent manner.
Molostvov G, Gachechiladze M, Shaaban AM, Hayward S, Dean I, Dias IHK, Badr N, Danial I, Mohammed F, Novitskaya V, Paniushkina L, Speirs V, Hanby A, Nazarenko I, Withers DR, van Laere S, Long HM, Berditchevski F.
Cell Rep. 2023 Mar 28;42(3):112207. doi: 10.1016/j.celrep.2023.112207. Epub 2023 Mar 3.

A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression.
Rigamonti N, Veitonmäki N, Domke C, Barsin S, Jetzer S, Abdelmotaleb O, Bessey R, Lekishvili T, Malvezzi F, Gachechiladze M, Behe M, Levitsky V, Trail PA.
Cancer Immunol Res. 2022 May 3;10(5):626-640. doi: 10.1158/2326-6066.CIR-21-0553.

Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
Gachechiladze M, Skarda J, Bouchalova K, Soltermann A, Joerger M.
Front Oncol. 2020 Nov 3;10:581217. doi: 10.3389/fonc.2020.581217.

Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
Gachechiladze M, Škarda J, Skanderová D, Überall I, Kolek V, Smičkova P, Vojta P, Vbrková J, Hajdúch M, Shani I, Kolář Z, Stahel R, Weder W, Rulle U, Soltermann A, Joerger M.
Lung Cancer. 2020 Sep;147:30-38. doi: 10.1016/j.lungcan.2020.06.025. Epub 2020 Jun 23.

The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer.
Hayward S, Gachechiladze M, Badr N, Andrijes R, Molostvov G, Paniushkina L, Sopikova B, Slobodová Z, Mgebrishvili G, Sharma N, Horimoto Y, Burg D, Robertson G, Hanby A, Hoar F, Rea D, Eckhardt BL, Ueno NT, Nazarenko I, Long HM, van Laere S, Shaaban AM, Berditchevski F.
J Pathol. 2020 May;251(1):63-73. doi: 10.1002/path.5415. Epub 2020 Mar 24.

Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Majera D, Skrott Z, Bouchal J, Bartkova J, Simkova D, Gachechiladze M, Steigerova J, Kurfurstova D, Gursky J, Korinkova G, Cwiertka K, Hodny Z, Mistrik M, Bartek
J. Prostate. 2019 Mar;79(4):352-362. doi: 10.1002/pros.23741. Epub 2018 Nov 29.